Abstract
High level activation of p53-dependent transcription occurs following cellular exposure to genotoxic damaging agents such as UV-C, while ionizing radiation damage does not induce a similarly potent induction of p53-dependent gene expression. Reasoning that one of the major differences between UV-C and ionizing radiation damage is that the latter does not inhibit general transcription, we attempted to reconstitute p53-dependent gene expression in ionizing irradiated cells by co-treatment with selected transcription inhibitors that alone do not activate p53. p53-dependent transcription can be dramatically enhanced by the treatment of ionizing irradiated cells with low doses of DRB, which on its own does not induce p53 activity. The mechanism of ionizing radiation-dependent activation of p53-dependent transcription using DRB is more likely due to inhibition of gene transcription rather than prolonged DNA damage, as the non-genotoxic and general transcription inhibitor Roscovitine also synergistically activates p53 function in ionizing irradiated cells. These results identify two distinct signal transduction pathways that cooperate to fully activate p53-dependent gene expression: one responding to lesions induced by ionizing radiation and the second being a kinase pathway that regulates general RNA Polymerase II activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- DRB:
-
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole
- UV:
-
ultraviolet radiation
References
Abarzua P, LoSardo JE, Gubler ML and Neri A. . 1995 Cancer Res. 55: 3490–3494.
Abraham J, Kelly J, Thibault P and Benchimol S. . 2000 J. Mol. Biol. 295: 853–864.
Allende JE and Allende CC. . 1995 FASEB J. 9: 313–323.
Andera L and Wasylyk B. . 1997 Mol. Med. 3: 852–863.
Bellamy CO, Clarke AR, Wyllie AH and Harrison DJ. . 1997a FASEB J. 11: 591–599.
Bellamy CO, Prost S, Wyllie AH and Harrison DJ. . 1997b J. Pathol. 183: 177–181.
Biedermann KA, Sun JR, Giaccia AJ, Tosto LM and Brown JM. . 1991 Proc. Natl. Acad. Sci. USA 88: 1394–1397.
Blaydes J, Vojtesek B, Bloomberg G and Hupp T. . 2000 Stress Responses: Methods and Protocols, Keyes S (ed). Humana Press.
Blaydes JP, Gire V, Rowson JM and Wynford-Thomas D. . 1997 Oncogene 14: 1859–1868.
Blaydes JP and Hupp TR. . 1998 Oncogene 17: 1045–1052.
Blaydes JP and Wynford-Thomas D. . 1998 Oncogene 16: 3317–3322.
Bond J, Haughton M, Blaydes J, Gire V, Wynford-Thomas D and Wyllie F. . 1996 Oncogene 13: 2097–2104.
Bond JA, Webley K, Wyllie FS, Jones CJ, Craig A, Hupp T and Wynford-Thomas D. . 1999 Oncogene 18: 3788–3792.
Bottger A, Bottger V, Sparks A, Liu WL, Howard SF and Lane DP. . 1997 Curr. Biol. 7: 860–869.
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW and Vogelstein B. . 1999 J. Clin. Invest. 104: 263–269.
Caron de Fromentel C, Gruel N, Venot C, Debussche L, Conseiller E, Dureuil C, Teillaud JL, Tocque B and Bracco L. . 1999 Oncogene 18: 551–557.
Chang D, Chen F, Zhang F, McKay BC and Ljungman M. . 1999 Cell Growth Differ. 10: 155–162.
Chehab NH, Malikzay A, Appel M and Halazonetis TD. . 2000 Genes Dev. 14: 278–288.
Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie, AH. . 1993 Nature 362: 849–852.
Craig AL, Blaydes JP, Burch LR, Thompson AM and Hupp TR. . 1999a Oncogene 18: 6305–6312.
Craig AL, Burch L, Vojtesek B, Mikutowska J, Thompson A and Hupp TR. . 1999b Biochem. J. 342: 133–141.
Cuddihy AR, Wong AH, Tam NW, Li S and Koromilas AE. . 1999 Oncogene 18: 2690–2702.
David-Pfeuty T. . 1999 Oncogene 18: 7409–7422.
Giaccia AJ and Kastan MB. . 1998 Genes Dev. 12: 2973–2983.
Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M and Del Sal G. . 1999 EMBO J. 18: 6462–6471.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ. . 1996 Nature 379: 88–91.
Hajduch M, Havlieek L, Vesely J, Novotny R, Mihal V and Strnad M. . 1999 Adv. Exp. Med. Biol. 457: 341–353.
Hao M, Lowy AM, Kapoor M, Deffie A, Liu G and Lozano G. . 1996 J. Biol. Chem. 271: 29380–29385.
Hardmeier R, Hoeger H, Fang-Kircher S, Khoschsorur A and Lubec G. . 1997 Proc. Natl. Acad. Sci. USA 94: 7572–7576.
Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW. . 2000 Science 287: 1824–1827.
Honda R and Yasuda H. . 1999 EMBO J. 18: 22–27.
Huang LC, Clarkin KC and Wahl GM. . 1996 Proc. Natl. Acad. Sci. USA 93: 4827–4832.
Hughes PE, Alexi T and Schreiber SS. . 1997 Neuroreport 8: v–xii.
Hupp TR and Lane DP. . 1995 J. Biol. Chem. 270: 18165–18174.
Hupp TR, Sparks A and Lane DP. . 1995 Cell 83: 237–245.
Kapoor M and Lozano G. . 1998 Proc. Natl. Acad. Sci. USA 95: 2834–2837.
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW. . 1991 Cancer Res. 51: 6304–6311.
Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace Jr AJ. . 1992 Cell 71: 587–597.
Koumenis C and Giaccia A. . 1997 Mol. Cell. Biol. 17: 7306–7316.
Kurokawa K, Tanaka T and Kato J. . 1999 Oncogene 18: 2718–2727.
Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R and Brady JN. . 1998 J. Biol. Chem. 273: 33048–33053.
Lavin MF, Concannon P and Gatti RA. . 1999 Cancer Res. 59: 3845–3849.
Levine AJ. . 1997 Cell 88: 323–331.
Linke SP, Clarkin KC, Di Leonardo A, Tsou A and Wahl GM. . 1996 Genes Dev. 10: 934–947.
Ljungman M and Zhang F. . 1996 Oncogene 13: 823–831.
Ljungman M, Zhang F, Chen F, Rainbow AJ and McKay BC. . 1999 Oncogene 18: 583–592.
Lu H, Taya Y, Ikeda M and Levine AJ. . 1998 Proc. Natl. Acad. Sci. USA 95: 6399–6402.
Lu X and Lane DP. . 1993 Cell 75: 765–778.
Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B and Jacks T. . 1995 Genes Dev. 9: 935–944.
Nitta M, Okamura H, Aizawa S and Yamaizumi M. . 1997 Oncogene 15: 561–568.
Pise-Masison CA, Radonovich M, Sakaguchi K, Appella E and Brady JN. . 1998 J. Virol. 72: 6348–6355.
Prigent C, Lasko DD, Kodama K, Woodgett JR and Lindahl T. . 1992 EMBO J. 11: 2925–2933.
Reavy HJ, Traynor NJ and Gibbs NK. . 1997 Photochem. Photobiol. 66: 368–373.
Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP and Hay RT. . 1999 EMBO J. 18: 6455–6461.
Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW and Appella E. . 1998 Genes Dev. 12: 2831–2841.
Sakaguchi K, Saito S, Higashimoto Y, Roy S, Anderson CW and Appella E. . 2000 J. Biol. Chem. 275: 9278–9283.
Sakhi S, Bruce A, Sun N, Tocco G, Baudry M and Schreiber SS. . 1994 Proc. Natl. Acad. Sci. USA 91: 7525–7529.
Sakhi S, Bruce A, Sun N, Tocco G, Baudry M and Schreiber S. . 1997 Exp. Neurol. 145: 81–88.
Sankrithi N and Eskin A. . 1999 J. Neurochem. 72: 605–613.
Shieh SY, Ahn J, Tamai K, Taya Y and Prives C. . 2000 Genes Dev. 14: 289–300.
Shieh SY, Ikeda M, Taya Y and Prives C. . 1997 Cell 91: 325–334.
Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E and Kastan MB. . 1997 Genes Dev. 11: 3471–3481.
Stone-Wolff DS and Rossman TG. . 1981 Mutat. Res. 82: 147–157.
Tao W and Levine AJ. . 1999 Proc. Natl. Acad. Sci. USA 96: 6937–6941.
te Poele RH, Okorokov AL and Joel SP. . 1999 Oncogene 18: 5765–5772.
Thut CJ, Chen JL, Klemm R and Tjian R. . 1995 Science 267: 100–104.
Unger T, Sionov RV, Moallem E, Yee CL, Howley PM, Oren M and Haupt Y. . 1999 Oncogene 18: 3205–3212.
Wallace-Brodeur RR and Lowe SW. . 1999 Cell. Mol. Life Sci. 55: 64–75.
Waterman MJ, Stavridi ES, Waterman JL and Halazonetis TD. . 1998 Nat. Genet. 19: 175–178.
Webley K, Bond JA, Jones CJ, Blaydes JP, Craig A, Hupp T and Wynford-Thomas D. . 2000 Mol. Cell. Biol. 20: 2803–2808.
Wesierska-Gadek J, Wang ZQ and Schmid G. . 1999 Cancer Res. 59: 28–34.
Williams AC, Collard TJ and Paraskeva C. . 1999 Oncogene 18: 3199–3204.
Yamaizumi M and Sugano T. . 1994 Oncogene 9: 2775–2784.
Yankulov K, Yamashita K, Roy R, Egly JM and Bentley DL. . 1995 J. Biol. Chem. 270: 23922–23925.
Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Shioya H, Utsugisawa Y, Shi Y, Weichselbaum R and Kufe D. . 1999a Oncogene 18: 5714–5717.
Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Shioya H, Utsugisawa Y, Yokoyama K, Weichselbaum R, Shi Y and Kufe D. . 1999b J. Biol. Chem. 274: 1883–1886.
Acknowledgements
This work was supported by the UK Medical Research Council, the Cancer Research Campaign, Tenovus-Scotland, and by Moravian Biotechnologies.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blaydes, J., Craig, A., Wallace, M. et al. Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene 19, 3829–3839 (2000). https://doi.org/10.1038/sj.onc.1203773
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203773
Keywords
This article is cited by
-
CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells
Cell Death & Disease (2020)
-
Evaluation of cytotoxic activity of titanocene difluorides and determination of their mechanism of action in ovarian cancer cells
Investigational New Drugs (2015)
-
Transcription — guarding the genome by sensing DNA damage
Nature Reviews Cancer (2004)
-
Hypoxia attenuates the p53 response to cellular damage
Oncogene (2003)
-
Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway
Oncogene (2002)